Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where
Dr Lal PathLabs Ltd
-(LALPATHLAB)
XNSE:LALPATHLAB, XBOM:LALPATHLAB
Dr Lal PathLabs Ltd Q2 FY24 Earnings Conference Call Insights
Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q2 FY24 Earnings Concall Financial Performance Revenue for Q2 FY24 was INR601 crores, up
Dr Lal Pathlabs Ltd Q1FY24; 45% rise in Profits.
Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where
Dr Lal PathLabs Ltd (LALPATHLAB) Q4 FY23 Earnings Concall Transcript
Dr Lal PathLabs Ltd (NSE:LALPATHLAB) Q4 FY23 Earnings Concall dated May. 11, 2023. Corporate Participants: Hon. Brig. Dr. Arvind Lal -- Executive Chairman Om
Dr Lal PathLabs Ltd Q4 FY23 Earnings Conference Call Insights
Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q4 FY23 Earnings Concall Q&A Highlights: [00:17:48] Rahul Agarwal from InCred Capital asked if
Earnings Summary Of Dr. Lal Pathlabs Limited For Q4 FY23
Dr. Lal Pathlabs Limited is a healthcare diagnostics service provider headquartered in India. The company offers a wide range of diagnostic and
Earnings | Dr Lal Path Labs Ltd (NSE:LALPATHLAB): Q3FY23 Results Out; Total Income fell 2% YoY
Dr Lal Path Labs Ltd (NSE:LALPATHLAB) is a leading diagnostic services provider in India. The company was founded in 1949 by Dr.
Dr Lal PathLabs Ltd Q3 FY23 Earnings Conference Call Insights
Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q3 FY23 Earnings Concall Q&A Highlights: [00:12:28] Dheeresh Pathak from WhiteOak asked about the
Dr. Lal PathLabs Limited Q3 FY23; Net Profit Down By 8%
Dr. Lal PathLabs Limited (NSE: LALPATHLAB) reported a Revenue from Operations of ₹489.4 Crores, a decline of 1.5% from the previous year.
Dr Lal PathLabs Ltd Q2 FY23 Earnings Conference Call Insights
https://youtu.be/lAaNZKEvjOc Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q2 FY23 Earnings Concall Q&A Highlights: [00:16:43] Rahul Agarwal with Incred Capital enquired
Dr Lal PathLabs Ltd (LALPATHLAB) Q2 FY23 Earnings ConCall Transcript
Dr Lal PathLabs Ltd (NSE:LALPATHLAB) Q2 FY23 Earnings Concall dated Nov. 08, 2022 Corporate participants: Arvind Lal -- Executive Chairman Om Prakash
Earnings Infographic: Dr. Lal PathLabs Q1 2023 revenue and profit decline
Dr. Lal PathLabs Ltd (NSE: LALPATHLAB), a leading provider of diagnostic and related healthcare services, has reported lower revenues and earnings for
Dr Lal PathLabs Limited Research Report
Stock Data Ticker: LALPATHLAB Exchange : NSE BSE: 539524 Industry: Diagnostic Price Performance Last 7 days 8.70% YTD -38.28% Last 12 months
Dr Lal PathLabs Ltd Q1 FY23 Earnings Conference Call Insights
https://youtu.be/GyHJJGLWdjg Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q1 FY23 Earnings Concall Management Update: LALPATHLAB said it clocked the highest quarterly
Dr Lal PathLabs Ltd (LALPATHLAB) Q1 FY23 Earnings Concall Transcript
Dr Lal PathLabs Ltd (NSE:LALPATHLAB) Q1 FY23 Earnings Concall dated Jul. 28, 2022 Corporate Participants: Arvind Lal -- Executive Chairman Om Prakash
Research Summary Dr Lal PathLabs Limited Q4 FY 2022
Overview Dr Lal PathLabs Limited is an Indian diagnostic company. It was incorporated in 1949. The headquarters is situated in Delhi, India. It
Dr Lal PathLabs Ltd Q4 FY22 Earnings Conference Call Insights
https://youtu.be/XGfFd6kLFCE Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q4 FY22 Earnings Concall Management Update: LALPATHLAB said it saw significant shift towards
Dr Lal PathLabs Ltd (LALPATHLAB) Q4 FY22 Earnings Concall Transcript
Dr Lal PathLabs Ltd (NSE: LALPATHLAB) Q4 FY22 Earnings Concall dated May. 17, 2022 Corporate Participants: Nishid Solanki -- Arvind Lal -- Executive Chairman Om
Dr Lal PathLabs Ltd Q3 FY22 Earnings Conference Call Insights
https://www.youtube.com/watch?v=q_lILVipT-E Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q3 FY22 Earnings Concall Management Update: The company is enhancing access of its